Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Gu W, et al. Among authors: tian y. Lancet Oncol. 2022 Oct;23(10):1249-1260. doi: 10.1016/S1470-2045(22)00507-1. Epub 2022 Sep 5. Lancet Oncol. 2022. PMID: 36075260 Clinical Trial.
A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.
Zhou T, Zeng SX, Ye DW, Wei Q, Zhang X, Huang YR, Ye ZQ, Yang Y, Zhang W, Tian Y, Zhou FJ, Jie J, Chen SP, Sun Y, Xie LP, Yao X, Na YQ, Sun YH. Zhou T, et al. Among authors: tian y. PLoS One. 2015 Jan 27;10(1):e0117002. doi: 10.1371/journal.pone.0117002. eCollection 2015. PLoS One. 2015. PMID: 25625938 Free PMC article. Clinical Trial.
Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
Chen R, Zhou LQ, Cai XB, Xie LP, Huang YR, He DL, Gao X, Xu CL, Ding Q, Wei Q, Yin CJ, Ren SC, Wang FB, Tian Y, Sun ZQ, Fu Q, Ma LL, Zheng JH, Ye ZQ, Ye DW, Xu DF, Hou JQ, Xu KX, Yuan JL, Gao X, Liu CX, Pan TJ, Sun YH; Chinese Prostate Cancer Consortium. Chen R, et al. Among authors: tian y. Asian J Androl. 2015 Nov-Dec;17(6):1017-21. doi: 10.4103/1008-682X.150846. Asian J Androl. 2015. PMID: 25926603 Free PMC article.
Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.
Chen R, Huang Y, Cai X, Xie L, He D, Zhou L, Xu C, Gao X, Ren S, Wang F, Ma L, Wei Q, Yin C, Tian Y, Sun Z, Fu Q, Ding Q, Zheng J, Ye Z, Ye D, Xu D, Hou J, Xu K, Yuan J, Gao X, Liu C, Pan T, Sun Y; Chinese Prostate Cancer Consortium. Chen R, et al. Among authors: tian y. PLoS One. 2015 Jun 19;10(6):e0130308. doi: 10.1371/journal.pone.0130308. eCollection 2015. PLoS One. 2015. PMID: 26091007 Free PMC article.
Enhanced recovery after surgery for radical cystectomy with ileal urinary diversion: a multi-institutional, randomized, controlled trial from the Chinese bladder cancer consortium.
Lin T, Li K, Liu H, Xue X, Xu N, Wei Y, Chen Z, Zhou X, Qi L, He W, Tong S, Jin F, Liu X, Wei Q, Han P, Gou X, He W, Zhang X, Yang G, Shen Z, Xu T, Xie X, Xue W, Cao M, Yang J, Hu J, Chen F, Li P, Li G, Xu T, Tian Y, Wang W, Song D, Shi L, Yang X, Yang Y, Shi B, Zhu Y, Liu X, Xing J, Wu Z, Zhang K, Li W, Liang C, Yang C, Li W, Qi J, Xu C, Xu W, Zhou L, Cai L, Xu E, Cai W, Weng M, Su Y, Zhou F, Jiang L, Liu Z, Chen Q, Pan T, Liu B, Zhou Y, Gao X, Qiu J, Situ J, Hu C, Chen S, Zheng Y, Huang J. Lin T, et al. Among authors: tian y. World J Urol. 2018 Jan;36(1):41-50. doi: 10.1007/s00345-017-2108-3. Epub 2017 Oct 28. World J Urol. 2018. PMID: 29080948 Clinical Trial.
Current status of diagnosis and treatment of bladder cancer in China - Analyses of Chinese Bladder Cancer Consortium database.
Li K, Lin T; Chinese Bladder Cancer Consortium; Xue W, Mu X, Xu E, Yang X, Chen F, Li G, Ma L, Wang G, Liang C, Shi H, Li M, Tang M, Xue X, Lv Y, Deng Y, Li C, Chen Z, Zhou X, Jin F, Liu X, Wei J, Shi L, Gou X, He W, Zhou L, Cai L, Jin B, Fu G, Kong X, Sun H, Tian Y, Feng L, Pan T, Wu Y, Wang D, Hao H, Shi B, Zhu Y, Wei Q, Han P, Wu C, Tian D, Ye Z, Liu Z, Wang Z, Tian J, Qi L, Chen M, Li W, Qi J, Wang G, Fu L, Sun Z, Luo G, Shen Z, Zhu Z, Xing J, Wu Z, Wei D, Chen X, Na Y, Guo H, Wang C, Lu Z, Kong C, Liu Y, Yang J, Hu J, Gao X, Li J, Yin C, Li P, Chen S, Du Z, Li J, Yan Y, Zhang X, Huang S, Zhou F, Zhang Z, Sun Y, Zeng S, Cen S, Zhou J, Li H, Wen J, Huang J. Li K, et al. Among authors: tian d, tian j, tian y. Asian J Urol. 2015 Apr;2(2):63-69. doi: 10.1016/j.ajur.2015.04.016. Epub 2015 Apr 16. Asian J Urol. 2015. PMID: 29264122 Free PMC article.
A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia.
Ye D, Huang Y, Zhou F, Xie K, Matveev V, Li C, Alexeev B, Tian Y, Qiu M, Li H, Zhou T, De Porre P, Yu M, Naini V, Liang H, Wu Z, Sun Y. Ye D, et al. Among authors: tian y. Asian J Urol. 2017 Apr;4(2):75-85. doi: 10.1016/j.ajur.2017.01.002. Epub 2017 Jan 23. Asian J Urol. 2017. PMID: 29264210 Free PMC article.
20,199 results
You have reached the last available page of results. Please see the User Guide for more information.